JP2014527506A - 糖尿病治療のための組み合わせ - Google Patents

糖尿病治療のための組み合わせ Download PDF

Info

Publication number
JP2014527506A
JP2014527506A JP2014513476A JP2014513476A JP2014527506A JP 2014527506 A JP2014527506 A JP 2014527506A JP 2014513476 A JP2014513476 A JP 2014513476A JP 2014513476 A JP2014513476 A JP 2014513476A JP 2014527506 A JP2014527506 A JP 2014527506A
Authority
JP
Japan
Prior art keywords
combination
metformin
diabetes
ascorbic acid
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014513476A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014527506A5 (ru
Inventor
ユリエヴィッチ レシコフ，セルゲイ
ユリエヴィッチ レシコフ，セルゲイ
セルゲーエフナ ヴィクリエワ，ニーナ
セルゲーエフナ ヴィクリエワ，ニーナ
ペトロヴィッチ クルチャトフ，セルゲイ
ペトロヴィッチ クルチャトフ，セルゲイ
Original Assignee
ユリエヴィッチ レシコフ，セルゲイ
ユリエヴィッチ レシコフ，セルゲイ
セルゲーエフナ ヴィクリエワ，ニーナ
セルゲーエフナ ヴィクリエワ，ニーナ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユリエヴィッチ レシコフ，セルゲイ, ユリエヴィッチ レシコフ，セルゲイ, セルゲーエフナ ヴィクリエワ，ニーナ, セルゲーエフナ ヴィクリエワ，ニーナ filed Critical ユリエヴィッチ レシコフ，セルゲイ
Publication of JP2014527506A publication Critical patent/JP2014527506A/ja
Publication of JP2014527506A5 publication Critical patent/JP2014527506A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
JP2014513476A 2011-06-02 2012-04-05 糖尿病治療のための組み合わせ Pending JP2014527506A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2011122374/15A RU2451506C1 (ru) 2011-06-02 2011-06-02 Комбинация для лечения сахарного диабета и его осложнений
RU2011122374 2011-06-02
PCT/RU2012/000254 WO2012166008A1 (en) 2011-06-02 2012-04-05 Combination for treatment of diabetes mellitus

Publications (2)

Publication Number Publication Date
JP2014527506A true JP2014527506A (ja) 2014-10-16
JP2014527506A5 JP2014527506A5 (ru) 2015-05-14

Family

ID=46231593

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014513476A Pending JP2014527506A (ja) 2011-06-02 2012-04-05 糖尿病治療のための組み合わせ

Country Status (7)

Country Link
EP (1) EP2714022A1 (ru)
JP (1) JP2014527506A (ru)
KR (1) KR101567660B1 (ru)
CN (1) CN103402506A (ru)
EA (1) EA028394B1 (ru)
RU (1) RU2451506C1 (ru)
WO (1) WO2012166008A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2548731C2 (ru) * 2012-10-24 2015-04-20 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Новосибирский Государственный Педагогический Университет" Средство и способ комплексной терапии больных сахарным диабетом
CN105263484B (zh) * 2013-05-24 2018-08-03 株式会社加龄.营养研究所 包含二甲双胍和二氢槲皮素的药物组合及其用于治疗癌症的用途
US10442610B2 (en) 2014-03-11 2019-10-15 Starbucks Corporation Pod-based restrictors and methods
CN105902761A (zh) * 2016-06-16 2016-08-31 河南中医学院 一种槐花珍在制备治疗高血糖和糖尿病药物中的应用
FR3062795B1 (fr) * 2017-02-16 2019-06-07 Valbiotis Principe actif pharmaceutique et utilisation en particulier dans la prevention et le traitement des dereglements metaboliques chez l'homme et l'animal.
RU2687256C1 (ru) * 2018-03-26 2019-05-08 Федеральное Государственное бюджетное образовательное учреждение высшего образования Дагестанский государственный медицинский университет Министерства здравоохранения Российской Федерации Даггосмедуниверситет Способ персонализированного лечения хронической болезни почек у больных с диабетической нефропатией

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002080362A (ja) * 2000-06-21 2002-03-19 Kao Corp Ｐｐａｒ依存的遺伝子転写活性化剤
JP2003300904A (ja) * 2002-04-05 2003-10-21 National Cardiovascular Center 循環器系障害の進展を抑制する医薬組成物
WO2007007757A1 (ja) * 2005-07-12 2007-01-18 Daiichi Sankyo Company, Limited PPARγアゴニストを含有する医薬組成物
JP2007505854A (ja) * 2003-09-23 2007-03-15 ディーエスエム アイピー アセッツ ビー．ブイ． 糖尿病の治療および予防用組成物
JP2007509035A (ja) * 2003-10-10 2007-04-12 レスバーロジックス コーポレイション Ｅｇｒ−１エンハンサー要素に関連する疾患の処置
JP2007262050A (ja) * 2005-12-16 2007-10-11 National Institute Of Advanced Industrial & Technology アディポネクチン産生増強剤
JP2008189681A (ja) * 2008-03-31 2008-08-21 Kao Corp 脂質代謝改善剤
WO2010089874A1 (ja) * 2009-02-05 2010-08-12 フジッコ株式会社 ＰＰＡＲ－γ発現増強剤、アディポネクチン産生促進剤、ＵＣＰ活性剤およびそれらを用いた医薬品・飲食品
WO2010118789A1 (en) * 2009-04-17 2010-10-21 Dsm Ip Assets B.V. Hydroxytyrosol combinations for enhancing mitochondrial function and energy production
WO2011036316A2 (es) * 2009-09-23 2011-03-31 Probelte Pharma, Sa Uso de extractos vegetales como prebióticos, composiciones y alimentos que los contienen
JP2011063557A (ja) * 2009-09-18 2011-03-31 Lion Corp Ｐｐａｒ活性化剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027982A1 (fr) * 1996-12-24 1998-07-02 Sumitomo Pharmaceuticals Co., Ltd. Composition contenant de l'acide ascorbique
SI0974356T1 (en) 1998-07-15 2003-12-31 Merck Sante Tablets comprising a combination of metformin and glibenclamide
KR20000019716A (ko) * 1998-09-15 2000-04-15 박호군 바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물
ITMI20002019A1 (it) 1999-09-17 2002-03-15 Novartis Ag Metodo per il trattemento dei disturbi metabolici, in particolare diabete oppure una malattia oppure una condizione associate con il diabete
AU2001276682A1 (en) * 2000-08-01 2002-02-13 Oryza Oil and Fat Chemical Co., ltd. Sugar absorption inhibitors and process for producing the same
RU2284829C2 (ru) * 2004-12-16 2006-10-10 Пятигорская государственная фармацевтическая академия Антидиабетический сбор
CA2596311A1 (en) * 2005-01-20 2006-07-27 Stephen Holt Herbal compositions containing hoodia
JP5246834B2 (ja) * 2005-12-27 2013-07-24 独立行政法人産業技術総合研究所 アディポネクチン産生強化剤
CN101176786A (zh) * 2006-11-08 2008-05-14 中国科学院上海生命科学研究院 增加胰岛素敏感性的方法和组合物
RU2413528C2 (ru) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
TW200903710A (en) 2007-07-11 2009-01-16 Promos Technologies Inc Manufacturing method for shallow trench isolation
US20090175973A1 (en) * 2007-09-05 2009-07-09 Nina Vikhrieva Coffee cherry compositions and methods for their use in the treatment of diabetes and diabetes related disorders
CN101250106B (zh) * 2008-03-27 2011-05-18 北京市农林科学院 一种提取绿原酸的方法
RU2378003C1 (ru) * 2008-06-06 2010-01-10 Сергей Юрьевич Лешков Фармацевтическая композиция на основе экстракта зеленой ягоды кофе, способ получения и применения
AU2009307753A1 (en) 2008-10-22 2010-04-29 Metaproteomics, Llc Novel mitochondrial uncoupling methods and compositions for enhancing adipocyte thermogenesis
WO2010134085A1 (en) * 2009-05-20 2010-11-25 Institute Of Life Sciences Pharmaceutical co-crystals of quercetin
CN101851221B (zh) * 2010-05-27 2012-09-05 东北林业大学 一种从落叶松中制备二氢槲皮素的方法

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002080362A (ja) * 2000-06-21 2002-03-19 Kao Corp Ｐｐａｒ依存的遺伝子転写活性化剤
JP2003300904A (ja) * 2002-04-05 2003-10-21 National Cardiovascular Center 循環器系障害の進展を抑制する医薬組成物
JP2007505854A (ja) * 2003-09-23 2007-03-15 ディーエスエム アイピー アセッツ ビー．ブイ． 糖尿病の治療および予防用組成物
JP2007509035A (ja) * 2003-10-10 2007-04-12 レスバーロジックス コーポレイション Ｅｇｒ−１エンハンサー要素に関連する疾患の処置
WO2007007757A1 (ja) * 2005-07-12 2007-01-18 Daiichi Sankyo Company, Limited PPARγアゴニストを含有する医薬組成物
JP2007262050A (ja) * 2005-12-16 2007-10-11 National Institute Of Advanced Industrial & Technology アディポネクチン産生増強剤
JP2008189681A (ja) * 2008-03-31 2008-08-21 Kao Corp 脂質代謝改善剤
WO2010089874A1 (ja) * 2009-02-05 2010-08-12 フジッコ株式会社 ＰＰＡＲ－γ発現増強剤、アディポネクチン産生促進剤、ＵＣＰ活性剤およびそれらを用いた医薬品・飲食品
WO2010118789A1 (en) * 2009-04-17 2010-10-21 Dsm Ip Assets B.V. Hydroxytyrosol combinations for enhancing mitochondrial function and energy production
JP2011063557A (ja) * 2009-09-18 2011-03-31 Lion Corp Ｐｐａｒ活性化剤
WO2011036316A2 (es) * 2009-09-23 2011-03-31 Probelte Pharma, Sa Uso de extractos vegetales como prebióticos, composiciones y alimentos que los contienen

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6016004151; Ｐｈｙｔｏｍｅｄｉｃｉｎｅ １６, 2009, １１１９-１１２６ *
JPN6016004153; Ｊｏｕｒｎａｌ　ｏｆ　Ａｇｒｉｃｕｌｔｕｒａｌ　ａｎｄ　Ｆｏｏｄ　Ｃｈｅｍｉｓｔｒｙ ５９（９）, 201105, ５１００-５１０８ *
JPN6016004155; Ｔｒｏｐｉｃａｌ　Ｊｏｕｒｎａｌ　ｏｆ　Ｐｈａｒｍａｃｅｕｔｉｃａｌ　Ｒｅｓｅａｒｃｈ ６　（１）, 2007, ６７１-６７８ *
JPN6016004156; Ｍｏｌ．　Ｎｕｔｒ．　Ｆｏｏｄ　Ｒｅｓ． ５４, 2010, ９９１-１００３ *

Also Published As

Publication number Publication date
EA028394B1 (ru) 2017-11-30
KR101567660B1 (ko) 2015-11-10
WO2012166008A1 (en) 2012-12-06
EA201301308A1 (ru) 2014-03-31
RU2451506C1 (ru) 2012-05-27
KR20140008452A (ko) 2014-01-21
CN103402506A (zh) 2013-11-20
EP2714022A1 (en) 2014-04-09

Similar Documents

Publication Publication Date Title
JP5249388B2 (ja) 糖尿病の治療及び予防のためのフタリド誘導体の使用
JP2014527506A (ja) 糖尿病治療のための組み合わせ
JP6954698B2 (ja) テトラメチルピラジンニトロン誘導体の糖尿病合併症疾患の予防と治療における応用
US20180333399A1 (en) Method of improving liver function
EP1905450A1 (en) Pharmaceutical composition containing ppar gamma agonist
WO2014135956A1 (en) Composition for use in the treatment of polycystic ovary syndrome
RU2664442C2 (ru) Способ снижения веса
KR20240037955A (ko) 혈당 조절 및 당뇨병 및 관련 질환의 치료 방법
CA3104916C (en) Pharmaceutical composition for preventing diabetes and use thereof
AU2016206292B2 (en) A method of improving liver function
KR100697097B1 (ko) 당뇨병 예방 또는 치료용 약학 조성물
WO2022061962A1 (zh) 一种l型氨基酸转运蛋白抑制剂或拮抗剂有效干预糖尿病的方法
Sadagoban Scientific Validation of Antidiabetic Activity of Modified Mucoadhesive Thiozolidinedione Derivative
CN110575447A (zh) 一种用于防治糖尿病的药物组合物及其用途
CN106310277A (zh) 含有降糖药物、阿司匹林及叶酸的药物组合物
MX2012014757A (es) Composicion farmaceutica de una meglitinida y una tiazolidinediona o sus sales farmaceuticamente aceptables y su uso.

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161004